Skip to main content

Topic

Pharmaceuticals

1,010 published works

  1. As Prescribed

    The Impact of the EU Pharma Package on the UK

    By Morgan Lewis

    As readers will be aware, at the end of 2025, the EU institutions agreed the text of the EU Pharma Package: the wholesale change to the pharmaceutical regime in the…

  2. Truth on the Market

    Borrowed Prices: Pharmaceuticals and the American Tab

    By Jeffrey E. Depp

    The Centers for Medicare & Medicaid Services (CMS) has proposed two sweeping Innovation Center models—the Global Benchmark for Efficient Drug Pricing Model (GLOBE) and the Guarding U.S. Medicare Against Rising…

  3. Duane Morris Vietnam

    VIETNAM – FOREIGN PHARMACEUTICAL COMPANIES – IMPORT AND DISTRIBUTION- WHAT YOU MUST KNOW

    By Dr. Oliver Massmann

    Vietnam’s pharmaceutical market is among the fastest growing in Asia. With a population of over 100 million, rising healthcare expenditure, an expanding middle class, and an increasingly sophisticated regulatory framework,…

  4. Drug Injury Watch

    Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs

    By Tom Lamb

    2026 Medical Article Links NAION to Ozempic, Wegovy, and Rybelsus, Again, With New Study (Posted by Tom Lamb at Drug Injury Watch) This drug safety issue of non-arteritic anterior ischemic optic neuropathy (NAION)…

  5. BioSlice Blog

    UK PMCPA releases new guidance on Package Deals: key takeaways for industry

    By Libby Amos-Stone, Emma Elliston

    The Prescription Medicines Code of Practice Authority (PMCPA) has published new guidance to provide clarity on the disclosure obligations and commercial governance expected from companies in relation to package deals…

  6. Global Policy Watch

    German Government launches new Pharma & MedTech Dialogue – Broad agenda, big hopes but unclear prospects

    By Dr. Dr. Adem Koyuncu, Maximilian Aretz

    Germany has kicked off a new Pharma and MedTech Dialogue that aims to develop new policies and regulatory reform proposals to re‑establish Germany as a competitive, innovation‑friendly location for life…

  7. Health Law Diagnosis

    Government Withdraws Appeal in 340B Rebate Pilot Program Litigation, Signaling Shift

    By Ivy Miller, Robinson+Cole's Health Law Group

    The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described below, took an unexpected turn as the federal government recently signaled that it…

  8. Drug & Device Law

    No Harm, No Foul: Medicine Consumers Got What They Paid For

    By Steven Boranian

    Simply charging a price higher than what plaintiffs want for an effective and non-defective medicine is not a consumer protection violation, and a recent order in the Northern District of…

  9. Big Molecule Watch

    Celltrion and Sandoz Launch Their Aflibercept Biosimilars in Europe

    By Allegra Padula

    On November 27, 2025, Celltrion announced that Health Canada approved EYDENZELT® (aflibercept-boav), a biosimilar referencing Regeneron’s EYLEA® (aflibercept), in both vial and pre-filled syringe form, to treat all indications approved…

  10. Big Molecule Watch

    Sun Pharma Launches ILUMYA® in India

    By Allegra Padula

    On December 1, 2025, Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) announced the launch of ILUMYA® (tildrakizumab-asmn) in India.  ILUMYA® is a humanized monoclonal antibody injection indicated for the treatment of adults…